3 Russell 2000 Stocks That Raise Red Flags for Investors
The Russell 2000 (^RUT) has long been a favorite hunting ground for investors looking to get in early on tomorrow's winners. These small-cap stocks can deliver explosive returns before the broader market catches on. But the flip side? Higher volatility, thinner liquidity, and a greater sensitivity to economic headwinds.
Picking the right small caps is no easy task. That's where StockStory comes in — to help you separate the signal from the noise. With that in mind, here are three Russell 2000 stocks we'd approach with caution, along with better alternatives worth your attention.
1. Monro Inc. (NASDAQ: MNRO)
Market Cap: $527.7 million
Founded as a single auto repair shop in Rochester, New York, Monro now operates hundreds of locations offering brake repairs, tire replacements, and oil changes. It's a staple in the automotive aftermarket, but the stock tells a different story.
Why We're Cautious: Monro trades at $17.56 per share, or 30.4 times forward earnings — a premium that seems hard to justify given slowing same-store sales and rising labor costs. "I've seen better value in a used tire," says Mark Delaney, a retail investor from Ohio. "The valuation is pricing in perfection, but the fundamentals are anything but." For a deeper dive, read our free research report on MNRO.
2. American Outdoor Brands (NASDAQ: AOUT)
Market Cap: $120.9 million
Spun off from Smith & Wesson in 2020, American Outdoor Brands sells outdoor and shooting sports accessories — but notably, not firearms themselves. The company has struggled to find its footing in a crowded market.
Why We're Cautious: At $9.57 per share, AOUT trades at 36.2 times forward P/E. "This is a company that's been drifting since day one," says Sarah Jenkins, a portfolio manager based in Chicago. "The brand lacks moat, and the valuation is a joke for a business with declining revenue." Check out our full research report for more on why AOUT doesn't make the cut.
3. Tandem Diabetes Care (NASDAQ: TNDM)
Market Cap: $1.33 billion
Tandem develops automated insulin delivery systems that sync with continuous glucose monitors — a life-changing technology for diabetes patients. But the market may already be pricing in years of future growth.
Why We're Cautious: TNDM shares trade at $19.58, or 25.7 times forward EV-to-EBITDA. "I love the product, but the stock feels like it's running on hype," says Dr. Lisa Tran, a healthcare analyst. "Competition from Abbott and Medtronic is heating up, and Tandem's margins are under pressure." For a complete analysis, see our free research report on TNDM.
One More Thing: Top 6 Stocks for This Week
The market is rotating fast — punishing overvalued names and rewarding quality. Our AI system flagged Palantir before it surged 1,662%, AppLovin before it climbed 753%, and Nvidia before its 1,178% run. Each week, it delivers 6 new names that pass the same rigorous tests. Get Our Top 6 Stocks for Free Here.
Past picks include now-household names like Nvidia (+1,326% between June 2020 and June 2025) and lesser-known winners like Tecnoglass (+1,754% over five years). Let StockStory help you find your next big winner.